CAR-T therapy trial for tough blood cancer pulled before starting
NCT ID NCT05909527
First seen Mar 29, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study aimed to test a new treatment called Anti-CD7 CAR-T cells for people with a hard-to-treat type of blood cancer (T-cell acute lymphoblastic leukemia/lymphoma) that had come back or not responded to standard therapy. The plan was to give the treatment to a small group of patients and watch for side effects and how well it worked. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hebei Yanda Hospital
Langfang, Hebei, 065000, China
Conditions
Explore the condition pages connected to this study.